Lilly Reports Phase 3b Data on Taltz and Zepbound Combination
Phase 3b data showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity.
Phase 3b data showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity.